Curated News
By: NewsRamp Editorial Staff
September 24, 2026
FamiCord's Bramble Bio to Manufacture VERIGRAFT's P-TEV for Phase II/III Trial
TLDR
- FamiCord's Bramble Bio gains a late-stage Phase II/III CDMO contract with VERIGRAFT, expanding its ATMP portfolio and securing low single-digit millions in revenue.
- Bramble Bio will transfer VERIGRAFT's P-TEV manufacturing process to its Warsaw GMP site, sourcing donated vein tissue and preparing for the TECVI-2 trial over 18 months.
- This collaboration advances P-TEV, a personalized tissue-engineered vein that could offer a curative treatment for severe chronic venous insufficiency without immunosuppression.
- VERIGRAFT's P-TEV uses decellularized donor veins reconditioned with a patient's own blood to create a personalized graft with a functioning valve.
Impact - Why it Matters
This partnership underscores the growing importance of specialized CDMO services in advancing personalized regenerative medicines. By securing manufacturing for P-TEV, VERIGRAFT moves closer to delivering a potentially curative treatment for severe chronic venous insufficiency, a condition affecting millions worldwide. For FamiCord, the deal validates its strategic expansion into high-value ATMP manufacturing and strengthens its position in the rapidly evolving cell and gene therapy market. Successful execution could accelerate patient access to innovative therapies and pave the way for similar collaborations.
Summary
FamiCord AG, Europe's leading cell bank and the third largest worldwide, has announced a manufacturing agreement between its CDMO brand Bramble Bio and Swedish clinical-stage biotechnology company VERIGRAFT AB. The collaboration will establish the GMP manufacturing process for VERIGRAFT's lead product candidate P-TEV, a personalized tissue-engineered vein with a functioning valve, at Bramble Bio's site in Warsaw, Poland. The agreement also covers support for sourcing and qualifying donated human vein tissue used as starting material. Technology-transfer activities will begin immediately, with the collaboration expected to run for approximately 18 months and an estimated contract value in the low single-digit millions of euros, potentially extendable based on clinical progress.
This deal adds a pivotal Phase II/III program to FamiCord's CDMO activities. The trial, named TECVI-2, is a randomized, controlled, open-label study designed to assess P-TEV's efficacy in patients with severe chronic venous insufficiency (CVI). Clinical sites are planned in Spain, Poland, and the Netherlands; the trial is already authorized in Spain and expected to start in Q1 2027. P-TEV is created by decellularizing donated venous tissue to preserve the native matrix and valve structure, then reconditioning it with the patient's own blood to create a personalized graft that restores venous function without immunosuppression.
Jakub Baran, CEO of FamiCord AG, commented, "The agreement with VERIGRAFT marks another concrete step in the development of our CDMO activities." Petter Bjorquist, CEO of VERIGRAFT, added that Bramble Bio combines specialist ATMP manufacturing expertise with the flexibility required for a complex personalized therapy. Simon Boa, Managing Director of Bramble Bio, called it a sweet spot deal. FamiCord, founded in Leipzig in 1997, has expanded into CDMO services for cell and gene therapies. VERIGRAFT, based in Gothenburg, Sweden, is a forerunner in industrialized tissue engineering. For more information, visit www.famicord.com and www.verigraft.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, FamiCord's Bramble Bio to Manufacture VERIGRAFT's P-TEV for Phase II/III Trial
